Q-omics provides the consensus-scored SERTM1 profile across patient tissues and cancer cell-line models. SERTM1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SERTM1 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, SERTM1 RNA expression shows 12,847 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, THCA, and TGCT as cancer lineages where SERTM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SERTM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SERTM1 survival associations across molecular data types. SERTM1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SERTM1 RNA expression–survival associations across cancer types. High SERTM1 expression shows unfavorable associations in KIRP, KIRC, HNSC and THCA, but favorable associations in UCEC and BRCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SERTM1 RNA expression.
This table summarizes SERTM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SERTM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SERTM1 shows lower tumor expression in THCA, STAD, KIRC, LUAD, LUSC and UCEC. The THCA box plot shows higher SERTM1 RNA expression in normal versus tumor tissue (log2 FC = −4.145, t-test p < 0.001).
This table shows molecular features associated with SERTM1 in patient tissues and cancer cell lines. In patient samples, SERTM1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SERTM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
